Caris Life Sciences, Inc. has grown revenue 63% a year over three years and 63% a year over five. Revenue growth, 3-year annual rate: +63% (Biotechnology median +17%). Revenue growth, 5-year rate: +63%, growth has slowed since the five-year average. Years of annual history on file: 3, FY2023 to FY2025, as filed.

CAICaris Life Sciences, Inc.

Healthcare

$29.66-9.0% 1Y

$29.66

$14.5552 weeks$32.95

Is it growing?

Mixed

Neither accelerating nor breaking down: revenue growing +85% year on year and operating margin widening (+51.0 points), but earnings down −111% year on year.

2 good, 1 to watch

Revenue trend+85% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings.

Earnings trend−111% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction+51.0 points operating

Trailing-twelve-month operating margin, 14.5% now against -36.6% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is CAI growing?

Caris Life Sciences, Inc. has grown revenue 63% a year over three years and 63% a year over five.

+63%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from fiscal-year columns as filed

Revenue growth, 5-year rate: +63%
Revenue growth, 5-year rate · +63% over three · growth has slowed since the five-year average
Years of annual history on file: 3
Years of annual history on file · FY2023 to FY2025, as filed

Details›